Search research articles
Contact Us
Filters
Showing results (51-60 of 132) with videos related to
Page
of 14
Sort By:
Tumori
|
April 25, 2015
Ampulla of Vater carcinoma in real-world clinical practice: a case series
Jacopo Giuliani, Paolo Piacentini, Andrea Bonetti
Recenti Progressi in Medicina
|
June 15, 2021
Covid-19 patients with cancer: what do they risk? Clinical, radiological and therapeutic features
Jacopo Giuliani, Beatrice Mantoan, Andrea Bonetti
Tumori
|
October 3, 2015
Management of advanced pancreatic cancer in daily clinical practice
Jacopo Giuliani, Paolo Piacentini, Andrea Bonetti
Anticancer Research
|
January 10, 2014
Targeted agents and oxaliplatin-containing regimens for the treatment of colon cancer
Andrea Bonetti, Jacopo Giuliani, Franco Muggia
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners
|
May 21, 2021
The cost-effectiveness of atezolizumab in first-line for metastatic triple negative breast cancer is heavily linked to PD-L1 level
Jacopo Giuliani, Beatrice Mantoan, Andrea Bonetti
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners
|
September 24, 2021
Cost-effectiveness of maintenance therapy after first-line treatment in metastatic colorectal cancer
Jacopo Giuliani, Beatrice Mantoan, Andrea Bonetti
Recenti Progressi in Medicina
|
June 27, 2022
Long-term survivors of metastatic colorectal cancer treated with trifluridine/tipiracil
Jacopo Giuliani, Beatrice Mantoan, Andrea Bonetti
Expert Review of Pharmacoeconomics & Outcomes Research
|
November 11, 2016
The European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) applied to pivotal phase III randomized-controlled trials of tyrosine kinase inhibitors in first-line for advanced non-small cell lung cancer with activating epidermal growth factor receptor mutations
Jacopo Giuliani, Andrea Remo, Andrea Bonetti
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners
|
September 28, 2021
The cost-effectiveness of new first-line therapies approved in advanced hepatocellular carcinoma
Jacopo Giuliani, Beatrice Mantoan, Andrea Bonetti
Frontiers in Veterinary Science
|
March 27, 2023
Botanicals as a zinc oxide alternative to protect intestinal cells from an <i>Escherichia coli</i> F4 infection <i>in vitro</i> by modulation of enterocyte inflammatory response and bacterial virulence
Andrea Bonetti, Andrea Piva, Ester Grilli
Page
of 14
Search research articles
Search
Showing results (51-60 of 132) with videos related to
Sort By:
Page
of 14
Tumori
|
April 25, 2015
Ampulla of Vater carcinoma in real-world clinical practice: a case series
Jacopo Giuliani, Paolo Piacentini, Andrea Bonetti
Recenti Progressi in Medicina
|
June 15, 2021
Covid-19 patients with cancer: what do they risk? Clinical, radiological and therapeutic features
Jacopo Giuliani, Beatrice Mantoan, Andrea Bonetti
Tumori
|
October 3, 2015
Management of advanced pancreatic cancer in daily clinical practice
Jacopo Giuliani, Paolo Piacentini, Andrea Bonetti
Anticancer Research
|
January 10, 2014
Targeted agents and oxaliplatin-containing regimens for the treatment of colon cancer
Andrea Bonetti, Jacopo Giuliani, Franco Muggia
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners
|
May 21, 2021
The cost-effectiveness of atezolizumab in first-line for metastatic triple negative breast cancer is heavily linked to PD-L1 level
Jacopo Giuliani, Beatrice Mantoan, Andrea Bonetti
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners
|
September 24, 2021
Cost-effectiveness of maintenance therapy after first-line treatment in metastatic colorectal cancer
Jacopo Giuliani, Beatrice Mantoan, Andrea Bonetti
Recenti Progressi in Medicina
|
June 27, 2022
Long-term survivors of metastatic colorectal cancer treated with trifluridine/tipiracil
Jacopo Giuliani, Beatrice Mantoan, Andrea Bonetti
Expert Review of Pharmacoeconomics & Outcomes Research
|
November 11, 2016
The European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) applied to pivotal phase III randomized-controlled trials of tyrosine kinase inhibitors in first-line for advanced non-small cell lung cancer with activating epidermal growth factor receptor mutations
Jacopo Giuliani, Andrea Remo, Andrea Bonetti
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners
|
September 28, 2021
The cost-effectiveness of new first-line therapies approved in advanced hepatocellular carcinoma
Jacopo Giuliani, Beatrice Mantoan, Andrea Bonetti
Frontiers in Veterinary Science
|
March 27, 2023
Botanicals as a zinc oxide alternative to protect intestinal cells from an <i>Escherichia coli</i> F4 infection <i>in vitro</i> by modulation of enterocyte inflammatory response and bacterial virulence
Andrea Bonetti, Andrea Piva, Ester Grilli
Page
of 14